Clinical outcomes after coronary angiography in nonalcoholic fatty liver disease
Savas Sarikaya, Yasar Turan, Mehmet Celikbilek – 26 April 2016
Combined liver–dual kidney transplant: Role in expanded donors
Marco Di Laudo, Matteo Ravaioli, Gaetano La Manna, Giorgia Comai, Matteo Cescon, Massimo Del Gaudio, Chiara Zanfi, Alessandro Cucchetti, Giorgio Ercolani, Antonio Daniele Pinna – 26 April 2016 – Kidney injury is a common clinical feature among liver transplantation (LT) candidates that heavily affects prognosis and complicates the surgical decision‐making process. Up to 20% of patients undergoing LT demonstrate some degree of renal impairment, and 2% will benefit from a combined liver‐kidney transplantation (LKT).
Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity
Dan Liu, Lei Cui, Yuan Wang, Guifang Yang, Jing He, Ruidong Hao, Chengpeng Fan, Mengmeng Qu, Zhepeng Liu, Min Wang, Lang Chen, Hui Li, Deyin Guo – 22 April 2016 – Hepatitis B viral infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Although several viral factors have been identified that may increase the risk for HCC development, the molecular mechanisms leading to the transformation of normal hepatocytes into cancer cells remain elusive.
Hepatology highlights
Jean‐François Dufour – 21 April 2016
Table of contents
21 April 2016
Stem/progenitor cells and reprogramming (plasticity) mechanisms in liver, biliary tree, and pancreas
Lola M. Reid – 21 April 2016
Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
Edward K. Geissler, Andreas A. Schnitzbauer, Hans J. Schlitt, for the SiLVER Study Group – 21 April 2016
New molecular interactions of c‐Myc in cholangiocarcinoma may open new therapeutic opportunities
Carmen Berasain, Maite G. Fernández‐Barrena, Matías A. Avila – 21 April 2016